Path: utzoo!utgpu!jarvis.csri.toronto.edu!cs.utexas.edu!uwm.edu!zaphod.mps.ohio-state.edu!usc!ucla-cs!pyrdc!lighthouse!lighthouse.com!rock@uunet.UU.NET
From: pyrdc!lighthouse!lighthouse.com!rock@uunet.UU.NET
Newsgroups: sci.med.aids
Subject: Washington HIV News 1/5
Message-ID: <32334@shemp.CS.UCLA.EDU>
Date: 24 Feb 90 22:59:34 GMT
Sender: news@CS.UCLA.EDU
Organization: Lighthouse Design, Ltd.
Lines: 104
Approved: ddodell@stjhmc.fidonet.org (David Dodell)
Copyright:    Copyright 1990, Sci.med.aids. Non-profit reproduction permitted.
Copyright:    All other rights reserved.
Archive-number: 1781

============================== 
|    WASHINGTON HIV NEWS     | 
============================== 
 
   Copyright (C) 1988, 1989, 1990 by Washington HIV News, all rights reserved.
 
   Permission is granted for non-commercial use only.
 
---------------------------
 
January 1990 - Vol 1, No 4
 
DEPARTMENTS:
 
        Opening -- Thanks for the help
        Distribution
        Staff
 
EDUCATION:
 
        Portrait of AIDS in the 1990s:  Lecture by Dr. Anthony Fauci
        Medical Update:  New treatment of HIV-infected individuals
        The saga of ddI
 
TREATMENT:
 
        Anti-retroviral protocols
          AZT and Acyclovir
          AZT & Acyclovir, ddI, and ddC combination study
          ddC (2',3'-dideoxycytidine) vs. AZT (Retrovir or Zidovudine) in
               patients with advanced ARC or AIDS
          ddI vs. AZT for people with AIDS or Advanced ARC with no or short-
               term prior AZT (ACTG 116)
          ddI vs. AZT for people with AIDS or Advanced ARC with long-term
               prior AZT (ACTG 117)
          ddI for people with AIDS or Advanced ARC who are intolerant to AZT
               (ACTG 118)
          ddI (2',3'-dideoxyinosine) for people with HIV dementia
          rCD4-IgG Conjugate ("Designer Gene") and AZT
          rCD4-IgG Conjugate ("Designer Gene")
 
        CMV Retinitis protocols
          Foscarnet for sight-threatening CMV Retinitis (ACTG 093)
 
        Pneumocystis carinii Pneumonia (PCP) protocols
          Aerosolized Pentamidine vs. Dapsone vs.
               Trimethoprim/Sulfamethoxazole (Bactrim) in combination with
               AZT in ARC patients (ACTG 081)
          Aerosolized Pentamidine vs. Trimethoprim/Sulfamethoxazole
               (Bactrim) in combination with AZT in AIDS patients (ACTG 021)
 
        Miscellaneous protocols
          Coping Response in HIV infection
          Foscarnet vs. Vidarabine to treat Acyclovir-resistant Herpes
               Simplex (ACTG 095)
          Neuropsychological testing
 
        Previously covered protocols
          Anti-retroviral protocols
          CMV Retinitis protocols
          Toxoplasmosis protocols
          Miscellaneous protocols
 
---------------------------

   The Washington HIV News is a newsletter containing information about 
dealing with HIV infection in the Washington, D.C. area.

   It has four main sections:

*   Education, with articles about different aspects of understanding HIV 
infection;

*   Treatment, which has a listing of treatment protocols that are open to new
patients at the different research facilities in the Washington area (like the
National Cancer Institute, National Institutes on Allergy and Infectious 
Diseases, George Washington University, Georgetown University, Veterans 
Affairs Medical Center, Whitman-Walker Clinic, etc.);

*   Services, which lists different things of practical interest to 
HIV-infected people; and

*   Departments, which contains the front page article, information on 
distribution, and the staff list and policy statements.
 
   The Washington HIV News is produced primarily for residents of the  
Washington Metropolitan area.  However, many of the protocols being run in  
Washington are ACTG (AIDS Clinical Trial Group) studies, which are run at  
many different centers across the country.  Therefore, just because a study  
is running at George Washington University in Washington doesn't mean it  
might not also be running at San Francisco General Hospital.  Call the  
NIH/NIAID AIDS Trial Line at 1-(800) TRIALS-A [874-2572] to check.
 
   Also, many of the NIH intramural protocols will pay to fly you in for 
treatment, ONCE YOU ARE ACCEPTED INTO THE STUDY.

   What this means is that IF the study permits non-residents and IF you 
qualify for it, you will have to pay to come to Washington for the screening 
interview, but if you are accepted, all of your travel and hotel bills after 
that will be paid for by NIH.  If in doubt, first read the requirements 
section to make sure you  qualify, and then call the person listed as the 
contact at NIH.
 
   ... Andrew Coile.